These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 22551539)

  • 21. Non-Small Cell Lung Cancer, Version 6.2015.
    Ettinger DS; Wood DE; Akerley W; Bazhenova LA; Borghaei H; Camidge DR; Cheney RT; Chirieac LR; D'Amico TA; Demmy TL; Dilling TJ; Dobelbower MC; Govindan R; Grannis FW; Horn L; Jahan TM; Komaki R; Krug LM; Lackner RP; Lanuti M; Lilenbaum R; Lin J; Loo BW; Martins R; Otterson GA; Patel JD; Pisters KM; Reckamp K; Riely GJ; Rohren E; Schild SE; Shapiro TA; Swanson SJ; Tauer K; Yang SC; Gregory K; Hughes M;
    J Natl Compr Canc Netw; 2015 May; 13(5):515-24. PubMed ID: 25964637
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Recent issues in first-line treatment of advanced non-small-cell lung cancer: Results of an International Expert Panel Meeting of the Italian Association of Thoracic Oncology.
    Gridelli C; Ardizzoni A; Douillard JY; Hanna N; Manegold C; Perrone F; Pirker R; Rosell R; Shepherd FA; De Petris L; Di Maio M; de Marinis F
    Lung Cancer; 2010 Jun; 68(3):319-31. PubMed ID: 20036027
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Treatment of advanced non-small-cell lung cancer with epidermal growth factor receptor (EGFR) mutation or ALK gene rearrangement: results of an international expert panel meeting of the Italian Association of Thoracic Oncology.
    Gridelli C; de Marinis F; Cappuzzo F; Di Maio M; Hirsch FR; Mok T; Morgillo F; Rosell R; Spigel DR; Yang JC; Ciardiello F
    Clin Lung Cancer; 2014 May; 15(3):173-81. PubMed ID: 24486058
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Impact of Reflex EGFR/ ALK Testing on Time to Treatment of Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer.
    Cheema PK; Menjak IB; Winterton-Perks Z; Raphael S; Cheng SY; Verma S; Muinuddin A; Freedman R; Toor N; Perera J; Anaka M; Victor JC
    J Oncol Pract; 2017 Feb; 13(2):e130-e138. PubMed ID: 28029301
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Chinese Medical Association guideline for clinical diagnosis and treatment of lung cancer (2023 edition)].
    ;
    Zhonghua Zhong Liu Za Zhi; 2023 Jul; 45(7):539-574. PubMed ID: 37460438
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Treatment of Elderly Patients With Non-Small-Cell Lung Cancer: Results of an International Expert Panel Meeting of the Italian Association of Thoracic Oncology.
    Gridelli C; Balducci L; Ciardiello F; Di Maio M; Felip E; Langer C; Lilenbaum RC; Perrone F; Senan S; de Marinis F
    Clin Lung Cancer; 2015 Sep; 16(5):325-33. PubMed ID: 25862554
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A multicenter survey of first-line treatment patterns and gene aberration test status of patients with unresectable Stage IIIB/IV nonsquamous non-small cell lung cancer in China (CTONG 1506).
    Zhou Q; Song Y; Zhang X; Chen GY; Zhong DS; Yu Z; Yu P; Zhang YP; Chen JH; Hu Y; Feng GS; Song X; Shi Q; Yang LL; Zhang PH; Wu YL
    BMC Cancer; 2017 Jul; 17(1):462. PubMed ID: 28673332
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Benefit of Targeted DNA Sequencing in Advanced Non-Small-Cell Lung Cancer Patients Without EGFR and ALK Alterations on Conventional Tests.
    Byeon S; Lee B; Park WY; Choi YL; Jung HA; Sun JM; Ahn JS; Ahn MJ; Park K; Lee SH
    Clin Lung Cancer; 2020 May; 21(3):e182-e190. PubMed ID: 31839532
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prognostic value of TP53 concurrent mutations for EGFR- TKIs and ALK-TKIs based targeted therapy in advanced non-small cell lung cancer: a meta-analysis.
    Qin K; Hou H; Liang Y; Zhang X
    BMC Cancer; 2020 Apr; 20(1):328. PubMed ID: 32299384
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Genomic Profiling of Advanced Non-Small Cell Lung Cancer in Community Settings: Gaps and Opportunities.
    Gutierrez ME; Choi K; Lanman RB; Licitra EJ; Skrzypczak SM; Pe Benito R; Wu T; Arunajadai S; Kaur S; Harper H; Pecora AL; Schultz EV; Goldberg SL
    Clin Lung Cancer; 2017 Nov; 18(6):651-659. PubMed ID: 28479369
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Computed Tomography Imaging Characteristics of Non-Small-Cell Lung Cancer With Anaplastic Lymphoma Kinase Rearrangements: A Systematic Review and Meta-Analysis.
    Mendoza DP; Stowell J; Muzikansky A; Shepard JO; Shaw AT; Digumarthy SR
    Clin Lung Cancer; 2019 Sep; 20(5):339-349. PubMed ID: 31164317
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Guidelines for HER2 testing in breast cancer: a national consensus of the Spanish Society of Pathology (SEAP) and the Spanish Society of Medical Oncology (SEOM).
    Albanell J; Andreu X; Calasanz MJ; Concha A; Corominas JM; García-Caballero T; López JA; López-Ríos F; Ramón y Cajal S; Vera-Sempere FJ; Colomer R; Martín M; Alba E; González-Martín A; Llombart A; Lluch A; Palacios J
    Clin Transl Oncol; 2009 Jun; 11(6):363-75. PubMed ID: 19531451
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Biomarkers in Non-Small Cell Lung Cancers: Indian Consensus Guidelines for Molecular Testing.
    Prabhash K; Advani SH; Batra U; Biswas B; Chougule A; Ghosh M; Muddu VK; Sahoo TP; Vaid AK
    Adv Ther; 2019 Apr; 36(4):766-785. PubMed ID: 30864106
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Guidelines for biomarker testing in gastroenteropancreatic neuroendocrine neoplasms: a national consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology.
    García-Carbonero R; Vilardell F; Jiménez-Fonseca P; González-Campora R; González E; Cuatrecasas M; Capdevila J; Aranda I; Barriuso J; Matías-Guiu X; ;
    Clin Transl Oncol; 2014 Mar; 16(3):243-56. PubMed ID: 23749327
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical features and therapeutic options in non-small cell lung cancer patients with concomitant mutations of EGFR, ALK, ROS1, KRAS or BRAF.
    Zhuang X; Zhao C; Li J; Su C; Chen X; Ren S; Li X; Zhou C
    Cancer Med; 2019 Jun; 8(6):2858-2866. PubMed ID: 31016879
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Molecular Pathology of Lung Cancer Cytology Specimens: A Concise Review.
    Jain D; Roy-Chowdhuri S
    Arch Pathol Lab Med; 2018 Sep; 142(9):1127-1133. PubMed ID: 29547001
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical practice guidelines for the treatment of unresectable non-small-cell lung cancer. Adopted on May 16, 1997 by the American Society of Clinical Oncology.
    J Clin Oncol; 1997 Aug; 15(8):2996-3018. PubMed ID: 9256144
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Second ESMO consensus conference on lung cancer: pathology and molecular biomarkers for non-small-cell lung cancer.
    Kerr KM; Bubendorf L; Edelman MJ; Marchetti A; Mok T; Novello S; O'Byrne K; Stahel R; Peters S; Felip E;
    Ann Oncol; 2014 Sep; 25(9):1681-1690. PubMed ID: 24718890
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Epidermal growth factor receptor and anaplastic lymphoma kinase testing and mutation prevalence in patients with advanced non-small cell lung cancer in Switzerland: A comprehensive evaluation of real world practices.
    Ess SM; Herrmann C; Frick H; Krapf M; Cerny T; Jochum W; Früh M
    Eur J Cancer Care (Engl); 2017 Nov; 26(6):. PubMed ID: 28557060
    [TBL] [Abstract][Full Text] [Related]  

  • 40. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
    Greenhalgh J; Dwan K; Boland A; Bates V; Vecchio F; Dundar Y; Jain P; Green JA
    Cochrane Database Syst Rev; 2016 May; (5):CD010383. PubMed ID: 27223332
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.